Why Startup Studios Are The Ultimate Builders Of Deep-Tech Ventures [Forbes]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Forbes
Unlike digital ventures, which can iterate and pivot quickly, deep-tech startups face long R&D cycles, capital-intensive prototyping, regulatory complexity and fragmented value chains. The road to commercialization is filled with hurdles that demand strategic execution and privileged access to industry networks. Traditional venture capital has struggled with deep tech because of its long time horizons and high risk-to-reward ratio. Many investors still hesitate to back projects that require a decade of development before seeing meaningful revenue. Meanwhile, solo founders often lack the infrastructure and strategic connections needed to scale their innovations beyond the lab. PROMOTED The Startup Studio Model This is where startup studios provide a solution. By building companies from the ground up, startup studios reduce risk, accelerate execution and optimize the startup journey through structured venture creation, pre-established networks and hands-on support. This model h
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.MarketBeat
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 144
- 12/17/25 - Form 4
- RXRX's page on the SEC website